Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada

A legfontosabb adatok

Ki végzi
Takeda
Hol
Ausztria, Belgium, Görögország, Hollandia, Izrael, Kanada, Lengyelország, Olaszország és Svédország15 helyszín, 9 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
159 fő vett részt
Kezdés
2023. jún. 19.
Befejezés
2024. márc. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2024. április 25.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • (Cohort 1) Resistant / Refractory or Intolerant:
  • Aged greater than or equal to (>=) 18 years at the time of the SOT
  • Received an SOT after January 1, 2016
  • Diagnosed with asymptomatic or symptomatic CMV infection any time after the SOT date
  • Required >=1 anti-CMV agent to manage CMV infection and were subsequently considered:; resistant to currently available anti-CMV agent; OR; refractory to currently available anti-CMV agent; OR; intolerant to currently available anti-CMV agent
  • Follow-up information is available for at least 12 months from the index date (that is, date when the participant was first considered resistant, refractory or intolerant to anti-CMV agent) or death, whichever occurs first
  • Provided written informed consent prior to the initiation of any study procedures (unless waiver was granted by the Institutional Ethical Committee [IEC]); (Cohort 2) Pre-emptive treatment for CMV viremia:
  • Aged >=18 years at the time of the SOT
  • Received an SOT after January 1, 2019
  • Diagnosed with CMV viremia any time after the SOT date and received pre-emptive anti-CMV agent
  • Follow-up information is available for at least 12 months from the index date (that is, date when the participant was first preemptively treated with an anti-CMV agent) or death, whichever occurs first
  • Provided written informed consent prior to the initiation of any study procedures (unless waiver was granted by the IEC)

Ki nem vehet részt

  • Diagnosed as being positive for human immunodeficiency virus before the SOT
  • Unable to demonstrate a minimum of 12 months of follow-up from the index date (example, incomplete information on dates showing follow-up time)
  • Participation in a clinical trial related to CMV treatment during the study period

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

9 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts.

A teljes eredeti leírásKevesebb

No study medicines will be provided to participants in this study.

A vizsgálat 2 csoportja

  • Cohort 1: Resistant, Refractory, or Intolerant (RRI) to Anti-CMV Treatment

    Participants who had an SOT after January 1, 2016 and must have developed post-transplant CMV infection and were subsequently characterized as RRI to currently available anti-CMV treatment at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.

  • Cohort 2: Pre-emptive CMV Treatment

    Participants who had an SOT after January 1, 2019, and who were preemptively treated for CMV at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multinational, Non-Interventional, Retrospective Study on CMV Infection Outcomes, Treatment Patterns and Healthcare Utilization Study (OTUS) Among Solid Organ Transplant (SOT) Recipients in Europe and Canada (OTUS SOT Extension in the EUCAN Countries: Austria, Belgium, Canada, Greece, Israel, Italy, Netherlands, Poland and Sweden)
A regiszteradat frissítve
2024. április 25.